Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants with Catecholaminergic Polymorphic Ventricular Tachycardia

Next Previous
Search
Trial Profile

A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants with Catecholaminergic Polymorphic Ventricular Tachycardia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRD 4730 (Primary)
  • Indications Polymorphic catecholergic ventricular tachycardia
  • Focus Adverse reactions
  • Sponsors Cardurion Pharmaceuticals

    • Most Recent Events

    • 10 Jan 2025 Planned End Date changed from 31 Dec 2024 to 30 Sep 2025.
    • 10 Jan 2025 Planned primary completion date changed from 29 Nov 2024 to 31 Jul 2025.
    • 16 Jul 2024 According to a Cardurion Pharmaceuticals media release, company announced it has raised a $260 million Series B financing led by Ascenta Capital and proceeds from the financing will be used to support later-stage clinical trials with the company's two lead drug candidates CRD-750 and CRD-4730.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top